IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer Disease - IGC Pharma, INC.

replay our FYE 2025 Financial and Operations Call

Live on June 30 at 11: 00 AM ET

Press

Releases

December 1, 2022

IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer Disease

Related Posts

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights – A Year of Transformative Progress in Alzheimer’s Innovation

June 30, 2025

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30, 2025

June 27, 2025

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

June 23, 2025

CEO Update

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights – A Year of Transformative Progress in Alzheimer’s Innovation

June 30, 2025

igc pharma

IGC PHARMA, INC. | 10-K FYE March 30, 2025

June 30, 2025